Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 1

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04322136Not ApplicableCompleted

AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion

Role: collaborator

NCT06626438Not ApplicableRecruiting

Treatable Traits in Interstitial Lung Disease

Role: collaborator

NCT05788081Phase 2Active Not Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Role: collaborator

NCT05329714Recruiting

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

Role: collaborator

NCT03793257Recruiting

The EXCEL Registry of Patients Requiring ECMO

Role: collaborator

NCT03945110Phase 1Completed

Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury

Role: collaborator

NCT04611555Unknown

ICF in Cochlear Implant Users

Role: collaborator

NCT04602780Completed

Evaluating the Revised WORQ in CI Users

Role: collaborator

All 8 trials loaded